Why Moderna stock fell 32% in December

Investors in the COVID-19 vaccine maker took some profits last month.

| More on:
A glass jar labelled COVID_19 vaccine sits on a bench with capsules and precriptions drugs.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

What happened

Shares of biotech Moderna (NASDAQ: MRNA), maker of a COVID-19 vaccine, dropped 31.6% in December, according to data from S&P Global Market Intelligence

For context, the S&P 500 Index (INDEXSP: .INX) returned 3.8% last month.

So what

We can attribute Moderna stock's 32% drop last month to profit taking. After all, shares were up a whopping 581% in 2020 through the end of November, so it wasn't surprising that some investors took some money off the table in December. Moderna stock ended the year with a 434% gain.  

Shares of Moderna began their long climb early in 2020 when the company announced that it was developing a vaccine to immunise against COVID-19, the disease caused by the novel coronavirus.

As the below chart shows, the stock had a sharp run-up in November. It skyrocketed 126% in that month, driven by a string of great news about mRNA-1273, which was then a messenger RNA-based vaccine candidate.

On 30 November, Moderna announced the positive final results from its phase 3 study. As I previously wrote, "It found its vaccine candidate to be 94.1% effective in preventing COVID-19, and it uncovered no serious safety concerns. Moreover, the company said that it had submitted a request with the US Food and Drug Administration (FDA) for Emergency Use Authorisation (EUA) for mRNA-1273."

Then on 18 December came "the big news": Moderna announced the FDA had authorised the emergency use of mRNA-1273. Shares, which had been moving downward throughout December, fell nearly 3% that day. The reason shares dropped on such terrific news is that this news was widely expected and already priced in during November.

The US distribution of the vaccine began the next day, and administration of the first of the two-dose vaccine started on 20 December.

MRNA Chart

Data by YCharts.

Now what

On 18 December, Moderna said that it expected to deliver about 20 million doses to the US government by the end of December 2020. It also expects to have between 100 million and 125 million doses available globally in the first quarter of 2021, with 85 to 100 million of those available in the US. A total of 200 million doses was ordered by the US government, which has the option to purchase up to an additional 300 million doses.

The rollout of Moderna's vaccine to the states was slower than anticipated in December, but that's not its fault. The federal government's Operation Warp Speed is in charge of distribution.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Should you invest $1,000 in Advanced Health Intelligence right now?

Before you buy Advanced Health Intelligence shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Advanced Health Intelligence wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Beth McKenna has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

An elderly man finds out he's made a mistake.
International Stock News

Warren Buffett's career in review: His worst investment decisions

Despite the wins, Buffett has also made plenty of errors in his long career.

Read more »

A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
International Stock News

Warren Buffett's career in review: His best investment decisions

Buffett's best buys are simply astonishing.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
International Stock News

Meta Platforms is ramping up data center and AI investments. Is the growth stock a buy now?

Let's take a look.

Read more »

A head shot of legendary investor Warren Buffett speaking into a microphone at an event.
International Stock News

Berkshire Hathaway stock plunges after Warren Buffett steps down. Is this a golden opportunity to buy?

Investors might be wondering whether they should be buying or selling Berkshire Hathaway stock now.

Read more »

Man with virtual white circles on his eye and AI written on top, symbolising artificial intelligence.
International Stock News

Where Will Alphabet Be in 5 Years?

Today, the lowest-valued stock in the "Magnificent Seven" is Alphabet, and it's not close.

Read more »

Silhouette of CEO standing in conference room looking out at cityscape.
International Stock News

Who is Warren Buffett's successor Greg Abel?

Buffett's successor has been in training for years.

Read more »

A young woman sits at her desk in deep contemplation with her hand to her chin while seriously considering information she is reading on her laptop.
International Stock News

Do Google's antitrust woes make Alphabet stock a buy, sell, or hold?

In the past year, Google lost two major antitrust cases aimed at the heart of its business.

Read more »

A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
International Stock News

What did we learn from Warren Buffett at Berkshire's AGM over the weekend?

Buffett's final words of wisdom are well worth reading.

Read more »